As of April 2024 Cellectis has a market cap of $0.18 Billion. This makes Cellectis the world's 6973th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $0.18 B | -14.51% |
2023 | $0.22 B | 125.29% |
2022 | $97.86 M | -74.45% |
2021 | $0.38 B | -69.96% |
2020 | $1.27 B | 70.95% |
2019 | $0.74 B | 1.91% |
2018 | $0.73 B | -27.38% |
2017 | $1.00 B | 66.46% |
2016 | $0.60 B | -43.61% |
2015 | $1.07 B | 145.21% |
2014 | $0.43 B | 554.04% |
2013 | $66.95 M |
On Apr 23rd, 2024 the market cap of Cellectis was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Regeneron Pharmaceuticals REGN | $99.58 B | 52,733.45% | ๐บ๐ธ USA |
uniQure QURE | $0.22 B | 20.55% | ๐ณ๐ฑ Netherlands |
Novavax NVAX | $0.58 B | 211.09% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | $0.45 B | 143.47% | ๐บ๐ธ USA |